The Israeli firm’s gene therapy asset has disappointed in an advanced ovarian cancer study, leaving experts skeptical of its potential in other tumors and the company turning to an earlier program.

Freeline’s FLT180a could still prove to be the best-in-class gene therapy for hemophilia B but its cash and time are running out as rivals grow closer to market.

Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.

Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.